Continuum Advisory LLC Sells 4,074 Shares of Johnson & Johnson $JNJ

Key Points

• Continuum Advisory reduced its Johnson & Johnson stake by 47.4%, selling 4,074 shares during the second quarter and retaining 4,515 shares valued at approximately $1.15 million.
• Analysts remain broadly bullish, with a “Moderate Buy” consensus and an average price target of $274.13; recent targets range as high as $300. Institutional investors own 69.55% of J&J’s stock.
• Johnson & Johnson exceeded quarterly earnings and revenue expectations, while maintaining a $1.34 quarterly dividend, equivalent to a 2.0% yield. However, insiders have sold 87,569 shares worth about $23.1 million over the past 90 days.

Continuum Advisory LLC cut its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 47.4% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,515 shares of the company's stock after selling 4,074 shares during the period. Continuum Advisory LLC's holdings in Johnson & Johnson were worth $1,147,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of JNJ. Safeguard Investment Advisory Group LLC boosted its stake in Johnson & Johnson by 11.0% during the 2nd quarter. Safeguard Investment Advisory Group LLC now owns 3,659 shares of the company's stock valued at $929,000 after purchasing an additional 362 shares during the last quarter. Round Rock Advisors LLC raised its position in shares of Johnson & Johnson by 0.4% during the 2nd quarter. Round Rock Advisors LLC now owns 10,503 shares of the company's stock valued at $2,667,000 after purchasing an additional 42 shares during the period. Nykredit A S purchased a new position in Johnson & Johnson in the 2nd quarter worth approximately $278,975,000. MBA Advisors LLC increased its holdings in shares of Johnson & Johnson by 2.2% in the second quarter. MBA Advisors LLC now owns 6,165 shares of the company's stock worth $1,566,000 after purchasing an additional 130 shares during the last quarter. Finally, Emergent Wealth Advisors LLC grew its holdings in Johnson & Johnson by 5.8% during the 2nd quarter. Emergent Wealth Advisors LLC now owns 3,639 shares of the company's stock valued at $923,000 after buying an additional 201 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

JNJ has been the subject of a number of recent research reports. Guggenheim raised their target price on shares of Johnson & Johnson from $270.00 to $287.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Wells Fargo & Company boosted their target price on shares of Johnson & Johnson from $272.00 to $282.00 and gave the stock an "overweight" rating in a report on Monday, August 3rd. Citigroup increased their price target on shares of Johnson & Johnson from $285.00 to $298.00 and gave the company a "buy" rating in a report on Wednesday, July 8th. The Goldman Sachs Group reissued a "buy" rating and set a $282.00 price objective on shares of Johnson & Johnson in a research note on Thursday, July 16th. Finally, Argus set a $300.00 price objective on Johnson & Johnson in a research note on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $274.13.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 23,054 shares of the company's stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the transaction, the executive vice president owned 23,003 shares in the company, valued at approximately $5,779,963.81. This represents a 50.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the sale, the executive vice president owned 25,447 shares of the company's stock, valued at $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 87,569 shares of company stock worth $23,064,544. 0.16% of the stock is owned by company insiders.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson received CE Marking in Europe for ACUVUE OASYS MAX 2-Week reusable contact lenses, expanding its Vision Care product portfolio. The approval could support future sales, though its immediate financial impact is likely limited. Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses
• Positive Sentiment: China approved Icotyde, J&J’s once-daily oral treatment for moderate-to-severe plaque psoriasis. The drug gives the company access to a large patient population and may attract patients who prefer an oral therapy to injectable alternatives, creating a potential growth catalyst. Could Icotyde Become Johnson & Johnson’s Next Blockbuster in China?
• Positive Sentiment: Investor-focused coverage continues to highlight J&J as a Dividend Aristocrat that has maintained and increased its payout through past crises, supporting its appeal as a defensive income stock. The company also recently exceeded quarterly earnings and revenue expectations. 3 Top Dividend Aristocrats To Own Near All-Time Highs
• Neutral Sentiment: J&J is trading near its 12-month high after a strong advance, indicating sustained market confidence but also leaving less room for upside without additional earnings growth.
• Negative Sentiment: Analysts are questioning whether the rally is losing momentum. With shares valued at roughly 31 times earnings, profit-taking or valuation concerns could weigh on the stock despite the company’s defensive qualities and new growth opportunities. JNJ Stock: Is the Rally Running Out of Steam?

Johnson & Johnson Stock Down 0.2%

Shares of JNJ opened at $265.91 on Friday. The firm has a fifty day moving average price of $263.03 and a 200-day moving average price of $245.93. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $640.82 billion, a P/E ratio of 30.81, a P/E/G ratio of 2.54 and a beta of 0.24. Johnson & Johnson has a 12-month low of $173.33 and a 12-month high of $281.07.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.84 by $0.06. The company had revenue of $25.31 billion for the quarter, compared to analysts' expectations of $25.06 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.Johnson & Johnson's revenue was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Equities research analysts expect that Johnson & Johnson will post 11.61 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were given a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 2.0%. The ex-dividend date of this dividend was Tuesday, August 25th. Johnson & Johnson's payout ratio is currently 62.11%.

Johnson & Johnson Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.